| HOME >> BIOLOGY >> TECHNOLOGY |
ST. LOUIS, June 10 /PRNewswire-FirstCall/ -- KV Pharmaceutical Company (NYSE: KVa/KVb), a fully integrated specialty pharmaceutical company that develops, manufactures, acquires and markets technology-differentiated branded products and generic/non-branded prescription pharmaceuticals, today reported that it has become aware of litigation filed by a smaller generic drug company, Lannett Company, Inc., challenging the patent rights associated with PrimaCare ONE(R), a prenatal vitamin product marketed by KV's Ther-Rx branded pharmaceutical business unit. KV has not yet been served in the lawsuit.
"We are reviewing the claims in this lawsuit and we will defend this and any other challenge to our patent rights vigorously," stated Marc S. Hermelin, KV's Chairman of the Board and Chief Executive Officer. "Our long-standing expertise in the development and marketing of both branded and generic/unbranded products positions us well to aggressively defend this type of lawsuit, which is not uncommon in our industry. In addition, we will continue to pursue various other strategies to meet the needs of patients in the therapeutic categories we serve with innovative and cost-effective products."
About KV Pharmaceutical Company
KV Pharmaceutical Company is a fully integrated specialty pharmaceutical company that develops, manufactures, markets and acquires technology- distinguished branded and generic/non-branded prescription pharmaceutical products. The Company markets its technology-distinguished products through ETHEX Corporation, a national leader in pharmaceuticals that compete with branded products, and Ther-Rx Corporation, its branded prescription pharmaceutical subsidiary.
For further information about KV Pharmaceutical Company, please visit the Company's corporate website at http://www.kvpharmaceutical.com.
Safe Harbor
The information in this release may contain va
'/>"/>
| SOURCE KV Pharmaceutical Company Copyright©2008 PR Newswire. All rights reserved |